# Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer

> **NCT05573373** · PHASE1 · UNKNOWN · sponsor: **Affiliated Hospital of Jiangnan University** · enrollment: 40 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- EGF-R Positive Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Parimparib
- **DRUG:** Chemotherapy drug
- **DRUG:** Targeted Therapy Agent

## Key facts

- **NCT ID:** NCT05573373
- **Lead sponsor:** Affiliated Hospital of Jiangnan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-20
- **Primary completion:** 2024-11-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05573373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05573373, "Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05573373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*